caa a22 4500 39756564X CHVBK 20180308164827.0 cr unu---uuuuu 161202e19961120xx s 000 0 eng 10.1093/jnci/88.22.1623 doi (NATIONALLICENCE)oxford-10.1093/jnci/88.22.1623 Clinical Trials in Relapsed Prostate Cancer: Defining the Target [Elektronische Daten] [Howard I. Scher, Madhu Mazumdar, William Kevin Kelly] A re-examination of the methods of developing new treatments for patients with prostate cancer whose disease has progressed during hormone therapy is necessitated by the following: 1) the impact of prostate-specific antigen (PSA) testing on patient selection, 2) the increasing number of studies using noncytotoxic approaches, and 3) the lack of validated methods to report outcomes. PSA monitoring after primary therapy has increased the number of patients referred for therapy with a rising value in this marker or an asymptomatic change in a radionuclide bone scan as the only manifestation(s) of relapse. The development of drugs for this population of patients presents a unique challenge because the classical criterion used to assess efficacy in the phase II setting, i.e., the presence of objective changes in measurable disease sites, frequently does not apply. Since no approach has been proven to prolong survival, the highest priority must be placed on developing new therapies. Standardizing the methods for evaluating treatments is also essential so that promising strategies are pursued and inactive therapies are not developed further. © Oxford University Press REVIEWS nationallicence Scher Howard I. Genitourinary Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan-Kettering Cancer Center Department of Medicine, Cornell University Medical College New York, NY aut Mazumdar Madhu Department of Biostatistics and Epidemiology, Memorial Sloan-Kettering Cancer Center New York, NY aut Kelly William Kevin Genitourinary Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan-Kettering Cancer Center Department of Medicine, Cornell University Medical College New York, NY aut JNCI: Journal of the National Cancer Institute Oxford University Press 88/22(1996-11-20), 1623-1634 0027-8874 88:22<1623 1996 88 jnci https://doi.org/10.1093/jnci/88.22.1623 text/html Onlinezugriff via DOI 1 review-article jats NATIONALLICENCE 856 40 https://doi.org/10.1093/jnci/88.22.1623 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Scher Howard I. Genitourinary Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan-Kettering Cancer Center Department of Medicine, Cornell University Medical College New York, NY aut NATIONALLICENCE 700 1- Mazumdar Madhu Department of Biostatistics and Epidemiology, Memorial Sloan-Kettering Cancer Center New York, NY aut NATIONALLICENCE 700 1- Kelly William Kevin Genitourinary Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan-Kettering Cancer Center Department of Medicine, Cornell University Medical College New York, NY aut NATIONALLICENCE 773 0- JNCI: Journal of the National Cancer Institute Oxford University Press 88/22(1996-11-20), 1623-1634 0027-8874 88:22<1623 1996 88 jnci Metadata rights reserved CC BY-NC-4.0 http://creativecommons.org/licenses/by-nc/4.0 nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-oxford